Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

NCT ID: NCT00601146

Last Updated: 2020-01-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 39 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-11-01
• Study Completion Date: 2019-12-01

Brief Summary

This research study is being done because patients with a history of chest radiation treatment for Hodgkin's disease have been shown to be at increased risk for developing lung cancer a number of years out from treatment. The risk appears to be further increased among patients with a smoking history. Currently, the practice is to recommend annual low-dose chest CT scans in survivors of Hodgkin's disease who have received prior chest radiation treatment and who have at least a moderate smoking history. In this study, the CT scans will be read and interpreted by the study radiologist, and the results recorded in a consistent manner.

Detailed Description

• Participants will undergo a chest computed tomography (CT) scan once a year for a 3-year period.

Conditions

Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SCREENING
• Blinding Strategy: NONE

Study Groups

Low-dose Chest CT screening

Annual low-dose Chest CT screening

Group Type: EXPERIMENTAL

chest computed tomography scan

Intervention Type: PROCEDURE

Once a year for three years

Interventions

chest computed tomography scan

Once a year for three years

Intervention Type: PROCEDURE

Other Intervention Names

CT scan

Eligibility Criteria

Inclusion Criteria

• 5 years or longer from initial Hodgkin's disease diagnosis
• Current age 18 or older
• Received mediastinal irradiation and/or alkylating-agent based chemotherapy
• Smoking history of 10-pack years or more, or current smoker
• Pre-approval from the participant's insurance company for the CT study

Exclusion Criteria

• Patients with a history of lung cancer
• Currently receiving treatment for another cancer diagnosis
• Known diagnosis of any metastatic cancer
• Pregnant women

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Brigham and Women's Hospital

OTHER

Sponsor Role: collaborator

Dana-Farber Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Andrea K. Ng, MD

Radiation Oncologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Andrea K. Ng, MD

Role: PRINCIPAL_INVESTIGATOR

Dana-Farber Cancer Institute/Brigham and Women's Hospital

Locations

Brigham and Women's Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Countries

United States

Other Identifiers

06-122

Identifier Type: -

Identifier Source: org_study_id